Agristim α for injection approved for marketing

June 2, 2025  Source: drugdu 76

"/
On May 29, Mywell Biopharmaceuticals (688062) announced that the marketing application for Agrastim α for injection submitted by its wholly-owned subsidiary Jiangsu Taikang Biotechnology Co., Ltd. was approved by the National Medical Products Administration.

The drug is suitable for adult patients with non-myeloid malignancies who are receiving myelosuppressive anticancer drugs that are prone to cause febrile neutropenia. The drug  can be used to reduce the incidence of infections manifested by febrile neutropenia.The marketed product is also the first domestically marketed G-CSF drug developed using long-acting albumin fusion technology.

In the first quarter of 2025, Mabwell Biopharmaceuticals achieved revenue of 44.79 million yuan and a net profit attributable to shareholders of the parent company of -292 million yuan.

https://finance.eastmoney.com/a/202505293418060776.html

By editor
Share: 

your submission has already been received.

OK

Subscribe

Please enter a valid Email address!

Submit

The most relevant industry news & insight will be sent to you every two weeks.